About the Journal

Biomolecular and Health Science Journal (BHSJ) E-ISSN: 2620-8636 is a scientific peer-reviewed and open-access journal which is relevant to health-related professions by the Faculty of Medicine Universitas Airlangga, Indonesia. The journal was established in 2018 and was previously hosted at https://e-journal.unair.ac.id/bhsj. Our mission is to support the advanced progress of the medical world by providing all academia, scientists, clinicians, and healthcare professionals of the media to publish their research work.

BHSJ provides a forum for original articles, review articles, case reports and will be published two times a year (April and October). Studies that focus on evaluating and understanding the complexity of medical importance are welcomed in BHSJ.

BHSJ has been accredited as a 2nd Grade Scientific Journal (SINTA 2) by the Ministry of Research, Technology, and Higher Education, Republic of Indonesia (RISTEKDIKTI RI) since January 2021 based on the Decree of the Director-General of Research and Development Strengthening RISTEK-BRIN No.B/1796/E5.2/K1.02.00/2020 on December 30th, 2020. This accreditation applies from Volume 1 Number 2 (2018 Issue) and is valid until December 30th, 2025.

We aim to establish an editorial process that is accurate and consistent and does not pompous or tedious. Our committee has the highest ethical standards in medical research. Therefore, it is required for authors to provide specific information such as informed consent, study protocols, authorship, and conflict of interest, including the studies that are adhered to general standards.
Current Issue

Jul-Dec 2022 - Volume 5 - Issue 2

Editor-in-Chief: Prof. Muhammad Miftahussurur, MD, Ph.D

Online ISSN: 2620-8636

Frequency: Two issues per year

△ eTOC Alert
Editorial Board

Editor-in-Chief:
Muhammad Miftahussurur, MD., Ph.D
Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Hospital Surabaya, Indonesia
Scopus: 56323903000

Honorary Editor:
Prof. Budi Santoso, MD., Ph.D
Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
Scopus: 57201498069

Achmad Chusnu Romdhoni, MD., Ph.D
Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
Scopus: 56086152000

Hanik Badriyah Hidayati, MD., Ph.D
Department of Neurology, Faculty of Medicine Airlangga University – Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
Scopus: 57194159504

Sulistia Wati, MD., Ph.D
Department of Public Health, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
Scopus: 57218346257

Editorial Board Members:
Prof. Dr. Hein Van Poppel
Urology, KU Leuven, Belgium
Scopus: 7006019341

Prof. Sohkiichi Matsumoto, D.D.S., Ph.D
Niigata University School of Medicine, Niigata, Japan
Scopus: 35414579600

Prof. Dr. Baharudin Abdullah
Department of Otorhinolaryngology-Head and Neck Surgery, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kalantan, Malaysia
Scopus: 14059434300
Prof. In Seok Moon  
Department of Otorhinolaryngology, Gangnam Severance Hospital, Yonsei University College of Medicine, Eonju-ro 211, Gangnam-gu, Seoul, 06273, Korea  
Scopus: 55953868500

Prof. Yoshio Yamaoka, MD., Ph.D.  
Department of Environmental and Preventive Medicine Oita University Faculty of Medicine, Yufu, Japan  
Scopus: 55183784100

Hoda Michel Malaty, M.D., M.P.H., Ph.D., F.A.C.G  
Department Baylor College of Medicine, Houston, Texas, United States  
Scopus: 7005911149

Prof. Delvac Oceandy, MD., Ph.D.  
Division of Cardiovascular Sciences, The University of Manchester, Manchester, United Kingdom  
Scopus: 6506557120

Prof. Maria Lucia Inge Lusida, MD., Ph.D.  
Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia  
Scopus: 7801547112

Prof. Mei Ling Tsai, MD., Ph.D.  
Department of Physiology, National Cheng Kung University, Taiwan, Province of China  
Scopus: 57154844500

Shamsul Ansari, Ph.D.  
Maharajgunj Medical Campus, Institute of Medicine, Nepal  
Scopus: 55523204000

Prof. Kuntaman, MD, Ph.D.  
Department of Medical Microbiology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia  
Scopus: 8700386400

Prof. Nasronudin, MD  
Division of Tropical and Infectious Disease – Department of Internal Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital Surabaya, Indonesia  
Scopus: 55516591900

Prof. Retno Handajani, MD., Ph.D.  
Department of Medical Biochemistry, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia  
Scopus: 6603094707
Prof. Nicolaas C. Budhiparama, MD., Ph.D
Faculty of Medicine, Leids Universitair Medisch Centrum, Leiden, Netherland
Scopus: 560910137700

Prof. Usman Hadi, MD., Ph.D
Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital
Surabaya, Indonesia
Scopus: 55804160500

Vo Phuoc Tuan, MD., Ph.D
Department of Endoscopy, Cho Ray Hospital, Ho Chi Minh City, Viet Nam
Scopus: 57195367045

Evariste Tshibangu Kabamba, MD., Ph.D
Osaka City University Graduate School of Medicine 1-4-3 Asahimachi, Abeno-ku, Osaka-shi, Osaka, Japan
Scopus: 57196485075

Prof. Dr. CHEAH Fook Choe, FASc
Faculty of Medicine, Universiti Kebangsaan Malaysia
Expertise: Paediatrics
Scopus ID: 6603939153

**Associate Editor:**

Purwo Sri Rejeki, MD., Ph.D
Department of Physiology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
Scopus: 57208052652

Astri Dewayani, MD. Ph.D
Department of Anatomy, Histology and Pharmacology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
Scopus: 57218165232

**Assistant Editor:**

Cindy Fiona Arilian Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
Total Leukocyte Count in *Rattus norvegicus* after Duffy Binding-Like 2β-Plasmodium falciparum Erythrocyte Membrane Protein 1 Recombinant Protein Injection: The way to a Peptide-based Malaria Vaccine Development

Putri, Dwi Ari Santi; Sullistyaningsih, Erna; Kusuma, Irawan Fajar; More


Completeness of Prescription Contributes to Prescribing Errors in Hospitals: Is this the Doctor’s Negligence?

Ningrum, Shely Oktavia Puspita; Prabasari, Mardhina Ratna; Chalidyanto, Djazuly


Moisturizing Nanoemulgel of Turmeric (*Curcuma longa*) Rhizome Extract Ameliorates Atopic Dermatitis-like Skin Lesions in Mice Model through Thymic Stromal Lymphopoietin, Interleukin-13, and Interleukin-17

Suryawati, Nyoman; Wardhana, Made; Baktia, I Made; More


The Correlation of Fibronectin and Vimentin Expression on Anthracycline-Based Neoadjuvant Chemotherapy Response in Stage IIIA and Luminal Subtype IIIB Breast Cancer

Nugroho, Feri; Budianto, Bachtiar M.; Suprabawati, Desak G.

How is Patient Safety Culture, Perceived Organizational Support, and Contextual Performance Impacts Adverse Events?
Yuniati, Dyah; Trisnawati, Annis Dwi; Rochmah, Thinni Nurul

Comparative Study between *Helicobacter pylori* East-Asian-Type with 39-bp Deletions
Sugiarto, Faizah; Nurrovida, Kartika; Wibowo, Idznika Nurannisa; More

Factors Related to Seeking Health Services in People with Mental Disorders and Psychological Problems
Adianti, Tala Puspita; Wardani, Tusy Novita Dwi; Wulandari, Ratna Dwi

Relation Between the Facial Injury Severity Scale Score and Length of Stay in Maxillofacial Fracture Patients at General Hospital in Surabaya
Ariobimo, Bonfilio Neltio; Dita, Muhammad Rafif Alfian; Nujum, Nurun
The Positive Relationship of Body Mass Index, Drain Production, and Tumor Necrosis Factor-alpha in Stage IIIB Breast Cancer Patients after Modified Radical Mastectomy
Wisnubroto, Justinus Dwi Pratjojo; Sunanto, Ester Hans

The Efficacy of Flexible Ureterorenoscopy Compared with Extracorporeal Shock Wave Lithotripsy for <20 mm Renal Stone: A Systematic Review and Meta-Analysis
Jamhari, Muhammad Arif; Santoso, Anugrah Dianfitrian; Soebadi, Mohammad Ayoedha

Postoperative Pain after Total Joint Arthroplasty: Pathophysiology and Current Pharmacological Pain Management
Soetjahjo, Bintang; Nefihancoro, Udi Heru; Ermawan, Rieva; More

Conservative Management of Internal Bleeding Following Trauma in an Immune Thrombocytopenic Purpura Child with COVID-19 Infection
Wati, Mita Erna; Yudsonio, Alvin Fajar; Dewi, Hidayati Utami; More
Original Article

Total Leukocyte Count in *Rattus norvegicus* after Duffy Binding-Like 2β-*Plasmodium falciparum* Erythrocyte Membrane Protein 1 Recombinant Protein Injection: The way to a Peptide-based Malaria Vaccine Development

Dwi Ari Santi Putri, Erma Sulistyaningsih, Irawan Fajar Kusuma, Rosita Dewi

INTRODUCTION

Malaria, a disease caused by the *Plasmodium* parasite and transmitted by the female *Anopheles* mosquito, is a major health problem. World Health Organization reported approximately 229 million malaria cases in 2019, with an estimated death number of 409,000 cases. As much as 63% of all malaria cases in Indonesia were caused by *Plasmodium falciparum*, the rest were caused by *Plasmodium vivax*, and only a small portion was caused by *Plasmodium malariae*, *Plasmodium ovale*, and *Plasmodium knowlesi*. Severe malaria due to *P. falciparum* is mediated by *P. falciparum* erythrocyte membrane protein 1 (PfEMP1) that is expressed on the surface of infected red blood cells (iRBCs). The adhesion between iRBCs and vascular endothelial cell receptors is known as the cytoadherence mechanism, which may occur in the microcirculation of vital organs.

**ABSTRACT**

Severe malaria caused by *Plasmodium falciparum* is mediated by the *P. falciparum* erythrocyte membrane protein 1 (PfEMP1). It has a DBL2β domain that specifically binds to the intercellular adhesion molecule-1 (ICAM-1) receptor that lies in endothelial cells of many vital organs and is involved in malaria pathogenesis. Antibody against the DBL2β-PfEMP1 protein correlates with a reduced risk of severe malaria, making it a potential malaria vaccine candidate. This study aimed to examine total leukocytes after serial DBL2β-PfEMP1 recombinant protein injection to determine its immunogenicity. Settings and Design: This was an experimental study using pre-post control groups design. **Methods:** Samples were male rats aged 2-3 months with a weight of 150-350 g. Rats were injected 3x with 100 µg, 150 µg, and 200 µg of the purified DBL2β-PfEMP1 recombinant protein in the three-weeks interval. Blood samples were collected on days 0, 8, 29, and 50, and total leukocytes were counted using the improved Neubauer counting chamber and observed under a microscope. The data were analyzed using the Friedman test, Kruskal Wallis test, and Mann-Whitney test. **Results:** The lowest leukocyte level was at the pre-injection, and the highest level was after the third injection. There was a significant increase in leukocytes (*P* < 0.05) in all treatment groups but no increase in the control group. A dose of 100 µg of DBL2β-PfEMP1 recombinant protein showed the best response in inducing the increase of total leukocytes. **Conclusion:** The DBL2β-PfEMP1 recombinant protein could induce the higher leukocyte level in each injection, especially after the third injection.

**KEYWORDS:** Duffy binding-like domain, leukocyte, malaria vaccine candidate, protein
This mechanism will cause damage to various related organs. Furthermore, there is the adhesion of iRBC to normal erythrocytes, called a rosetting mechanism. In addition to inhibiting circulation or blood flow in infected vital organs, the cytoadherence and rosetting mechanisms will prevent iRBC from being destroyed in the spleen.

The PfEMP1 has a Duffy binding-like (DBL) domain for binding to its receptors. The DBL2β domain, a type of DBL domain, can bind intercellular adhesion molecule-1 (ICAM-1) and is associated with severe malaria. Study has shown that the antibody against the DBL2β recombinant protein may block the binding between DBL-2β and the ICAM-1 receptor and reduce the risk of severe malaria.

Malaria vaccine can be an essential approach for combating malaria, but the development of malaria vaccine is challenging due to the parasite’s complexity. A peptide-based vaccine could be an alternative. Several proteins were studied as malaria vaccine targets, including PfEMP-1. The essential role of the DBL-2β-PfEMP-1 in the pathogenesis of severe malaria makes it a candidate for a peptide-based malaria vaccine.

Vaccine-candidate protein should have immunogenic properties, meaning has the capacity to induce an immune response. One indicator of protein immunogenicity is the increase of leukocyte number after exposure to protein. A leukocyte is a protective unit that plays a vital role in the immune system to provoke an immune response. It depicts an immune response that becomes a defense against foreign substances. Leukocytes may represent either the innate or adaptive immune systems that have a role in cell-mediated activities, humoral activities, and memory cell activity that prevents reinfection.

Leukocytes can do phagocytosis, and antigen recognition, destroy pathogens through cytotoxic-induced apoptosis and start a complement cascade to lyse the pathogen. The increase in leukocytes also increases antibodies which cause the body’s immunity to be stronger. In this study, the total leukocytes were counted after serial injection of three different doses of the DBL2β-PfEMP-1 recombinant protein to determine its immunogenicity.

METHODS
Ethical clearance
The study received ethical approval from The Ethical Committee of the Faculty of Medicine, the University of Jember, with reference number No. 1560/H25.1.11/KE/2022.

Study design and animal sample
It was a true experimental design with a randomized pre-and posttest control group design. As many as 16 male Wistar rats (Rattus norvegicus), age 8–10 weeks, with a bodyweight of approximately 150–300 g, were provided for the study as calculated by resource equation methods. Rats were acclimatized at laboratory conditions with 30°C–35°C with a 12-h light cycle and standard feeding for 2 weeks.

The Duffy binding-like-2β-Plasmodium falciparum erythrocyte membrane protein 1 recombinant protein production and purification
The production of DBL-2β-PfEMP-1 recombinant protein was performed using the procedure conducted by Rachmania et al. (2020). The DBL-2β-PfEMP1 recombinant protein was expressed in Escherichia coli BL21 (DE3). It started with culturing the DBL2β-PfEMP1 clone cells in Luria-Bertani media containing kanamycin at 37°C with a shaker incubator at 150 rpm until it reached an optical density with a wavelength of 600 nm 0.6–0.8. The expression was induced using isopropyl β-D-1-thiogalactopyranoside (IPTG). The culture was harvested, and the DBL-2β-PfEMP-1 recombinant protein was extracted by lysozyme addition and sonication.

The recombinant protein was subsequently purified based on affinity chromatography using Ni-NTA agarose, using an elution buffer containing 60- and 100-mM imidazole, respectively. The purified recombinant protein was further analyzed for its concentration using the Bradford protein assay and electrophorized with sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) 12.5% in 50 V for 45 min for upper gel and 80 V for 120 min for lower gel. The gel was stained using Coomassie brilliant blue.

Experimental design
After 2 weeks of acclimatization, 16 male rats were randomly divided into control groups and three treatment groups. A control group was injected with 0.9% NaCl, and the three treatment groups were injected subcutaneously with 100, 150, and 200 µg of purified DBL-2β-PfEMP-1 recombinant protein, respectively. Complete Freund’s adjuvant and incomplete Freund’s adjuvant were added to the protein using a ratio of 1:1 for primary and secondary injection, respectively. The injection was delivered subcutaneously on days 0, 21, and 42. The sera were collected using sterile capillaire on an orbital vein on days 0, 8, 29, and 50 for total leukocyte counts.

Total leukocyte counts
The total leukocyte counts were conducted using the improved Neubauer counting chamber with a 1:20 dilution of Turk solution and observed under a × 10 and × 40 microscope. The calculation was performed using the formula:

Leukocytes count per mm³ = (number of counted cells/volume of squares) × dilution factor.
Data analysis
The data analysis was performed with Statistical Package for The Social Sciences (SPSS) version 24.0 IBM, Armonk, New York, United States using the Friedman test, Kruskal–Wallis test, and Mann–Whitney test due to its normality and homogeneity tests with the significance value of 5% and $P < 0.05$ was considered statistically significant. The Friedman test was conducted to examine the significant difference between the preinjection and postinjection. The difference of leukocyte count among groups was determined with Kruskal–Wallis test then continued by Mann–Whitney pairwise comparison to analyze the significance between groups.

RESULTS

The Duffy binding-like-2β-Plasmodium falciparum erythrocyte membrane protein 1 recombinant protein production and purification

The target of DBL-2β-PfEMP-1 recombinant protein was ~72 kDa, as in the previous study. Visualization using SDS-PAGE confirmed it, and the highest concentration was obtained at the second round elution of 60-mM imidazole (E2.2) [Figure 1].

Leukocyte count

Figure 2 shows the average leukocyte counts in the control and treatment groups on pre- and serial postinjection of different doses of purified DBL-2β-PfEMP-1 recombinant protein. There was an increase in the average leukocyte counts in the treatment group injected with different doses of purified DBL-2β-PfEMP-1 protein. The leukocyte counts increased progressively with injection frequency, with the highest increase of leukocyte counts reached after the third recombinant protein injection. Furthermore, a dose of 100 µg of purified DBL-2β-PfEMP-1 recombinant protein showed the highest increase in leukocyte count.

Data analysis

The data analysis showed a normal distribution ($P > 0.05$) in the Shapiro–Wilk test but was not homogeneous in the Levene test ($P < 0.05$). The Friedman test analysis on the difference in leukocyte counts on pre- and postinjection of purified DBL-2β-PfEMP-1 recombinant protein showed a significant difference between groups ($P = 0.000$). The test also reported that the rank of average leukocyte counts from the lowest to the highest was preinjection (day 0), postfirst injection (day 8), postsecond injection (day 29), and postthird injection (day 50). Furthermore, an analysis of the difference between the control group and treatment groups was performed using the Kruskal–Wallis test showed no significant difference between groups at preinjection and postfirst injection. However, the Mann–Whitney test showed a significant difference in postsecond and third injections [Figure 3]. The Mann–Whitney test of the group’s difference is shown in Figure 3. After the first protein injection, only the dose of 150 µg recombinant protein differed from the control group. Meanwhile, after the second and third protein injection, all doses showed a significant difference from the control group. Furthermore, there was no difference between treatment groups in all injection periods.

DISCUSSION

An increase of total leukocytes in blood circulation is a sign of the body’s immune response to fight the pathogen. The study showed a significant increase in total leukocytes after injection of the purified DBL-2β-PfEMP-1 recombinant protein.
DBL-2β-PfEMP-1 recombinant protein \((P = 0.000)\). The Friedman test demonstrated that the lowest average of total leukocytes was at preinjection. The total leukocytes increased with the frequency of purified DBL-2β-PfEMP-1 recombinant protein injection. Studies reported that repeated immunogenic protein injection strengthens the immune response. The DBL-2β-PfEMP-1 recombinant protein is a protein candidate for a subunit malaria vaccine prepared by recombinant DNA technology. The subunit vaccine requires repeated injections to stimulate the immune response. The subunit type of vaccine does not produce an immune response as robust as a vaccine containing a live-attenuated virus or pathogen. Study on live-attenuated blood-stage malaria vaccine still challenging due to significant hurdles in completing initial testing in the human subject and also issues related to the safety, longevity of immune response, production's scalability, logistic storage, and distribution. A new approach of malaria vaccine design based on protein could be an important solution to solve the problems. The complexity of the Plasmodium life cycle makes the malaria vaccine development targeting on the specific stage of Plasmodium which causes pathogenesis, such as preerythrocytic stage, erythrocytic or blood stage, and transmission-blocking vaccine. Those vaccines could induce an immune response and prevent the mortality of malaria. The previous study using another subunit malarial vaccine candidate reported that repeated injections strengthen the immune response, which is indicated by high antibody titers after the third injection. Commensurable to this study, the leukocytes increased after repeated injections. The upsurge of leukocytes ensued in treatment groups but did not transpire in the control group. The normal total leukocyte of rats \((R. norvegicus)\) is 5000–13000 cells/mm³. Before injection, the leukocyte count of rats in this study varied between 5000 and 8000 cells/mm³, and it increased along with the frequency of protein injection up to 9600–13300 cells/mm³ after the third injection as presented in the treatment groups. There was no significant difference in total leukocytes between groups \(P = 0.283\) on day 0 before protein injection. Meanwhile, there was a significantly different on the days 29 and 50. Furthermore, there was a significant difference in total leukocytes within all treatment groups \([Table 1]\), indicating the remarkable increase in total leukocytes after the second and third protein injection. This is in accordance with previous studies that report a robust immune response and repeated injection. The injected DBL-2β-PfEMP-1 recombinant protein will be recognized as an antigen by antigen-presenting cells, which further activate leukocytes, particularly B lymphocytes and T lymphocytes, by clonal expansion and differentiation that reach the peak
Table 1: The average of leukocyte counts in control and treatment groups and the significance within group and between groups

<table>
<thead>
<tr>
<th>Group</th>
<th>Leukocyte count Average±SD (sel/mm³)</th>
<th>Significance within group (P)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Day 0 (preinjection)</td>
<td>Day 8 (post 1st injection)</td>
</tr>
<tr>
<td>Control group (0.9% NaCl)</td>
<td>5700±308</td>
<td>5433±1.608</td>
</tr>
<tr>
<td>100 µg recombinant protein</td>
<td>7238±1288</td>
<td>9250±1.337</td>
</tr>
<tr>
<td>150 µg recombinant protein</td>
<td>6938±532</td>
<td>8525±483</td>
</tr>
<tr>
<td>200 µg recombinant protein</td>
<td>6875±1.464</td>
<td>9338±506</td>
</tr>
<tr>
<td>Significance between group (P)</td>
<td>0.283</td>
<td>0.072</td>
</tr>
</tbody>
</table>

*There are significant differences (P<0.05) within group, **There are significant differences (P<0.05) between group. The leukocyte counts were measured in triplicate and the data were analyzed using the Kruskal-Wallis test. SD: Standard deviation

in 7 days postantigen exposure. Following the activation phase, the cellular and humoral immunity work as an effector phase which aims to eliminate antigens. Cellular immunity is mediated by helper T lymphocytes and cytotoxic T lymphocytes and plays an essential role in aiding macrophages to eliminate antigens and allowing B cells to produce antibodies and helper T-cells also secrete cytokines that may increase the number of leukocytes.

Previous studies on malaria vaccine candidates using merozoite surface protein-3 (MSP-3) in children showed that various doses led to disparities in inducing leukocyte counts. The increase of leukocytes was observed at a dose of 15 µg, while the increased dose up to 30 µg decreased leukocyte count. In this study, a significant increase of leukocytes after the first protein injection was observed at a dose of 150 µg only. However, all doses showed a significant increase in leukocytes after the second and third injections [Figure 3]. The high total leukocyte indicated a high immune response. Therefore, a dose of 100 µg of DBL-2β-PfEMP1 recombinant protein is suggested as the best dose to induce an immune response.

A vaccine candidate should be capable of inducing immune response either in primary or booster injection or both. A previous study using circumsporozoite protein as a vaccine candidate showed a significant increase in leukocytes along with injection frequency. In this study, the injection of purified DBL2β-PfEMP1 recombinant protein resulted in an increase of total leukocytes, which indicated the immunogenicity of the protein and could be a malaria vaccine candidate.

**Conclusion**

This study indicated that the DBL-2β-PfEMP1 recombinant protein induces the immune response demonstrated by the increase of leukocytes in rats and a dose of 100 µg of DBL-2β-PfEMP-1 recombinant protein was the best dose in inducing the increase of leukocytes. The ability of the DBL-2β-PfEMP-1 recombinant protein to induce a rat immune response suggested the potential of this protein as a candidate for a peptide-based malaria vaccine.

**Acknowledgments**

The author would like to thank the University of Jember for funding the study through Hibah Keris Malaria 2021 (Malaria Research Group Grant, 2021) No. 2662/UN25.3.1/LT/2021.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

Putri, et al.: Total leukocyte count in *Rattus norvegicus* after DBL2β-PfEMP1


